Beta Bionics: chief commercial officer Mark Hopman sold 370 shares

What happened Mark Hopman, chief commercial officer, sold 370 shares in an open market or private sale (code S) on Oct 1, 2026, at a weighted average price of $18.96 for $7,015, according to the Form 4 filed on Oct 5, 2026.

Key details

• Transaction date and price: Oct 1, 2026; weighted average sale price $18.96; reported price range $18.96 to $19.9599. (Footnote F2)
• Transaction type: open market or private sale (S).
• Shares owned after the transaction: not stated in the provided filing.
• Footnotes: F1 indicates the shares were sold pursuant to a Rule 10b5-1 plan adopted on Jun 10, 2026; F2 notes the weighted average and price range and that a full per-price breakdown is available on request.
• Filing timeliness: Form 4 filed Oct 5, 2026; the filing does not indicate it was late.

Why it may matter

• The filing reports a sale executed under a Rule 10b5-1 plan (per F1).
• A filing does not show why the insider traded or why the company acted.